FIG. 1



Effect of dose schedule of HDAC inhibitor on tumor cell death
% Cell death in Lymphoma cells
IV Continuous
51%
IV 2hr infusion
35%
Oral: Morning, Evening
4 hrs
4 hrs
9%
Oral: Morning, Afternoon
4 hrs
4 hrs
40%
Oral: TID
4 hrs
4 hrs
4 hrs
42%

FIG. 2




Continuous, IV or Oral dosing for 2 days : HDAC inhibitor at 2mg/kg
Annexin-V Positive Cells (%)
100
80
60
40
20
0
Jurkat
HCT116
4.68
6.57
50.57
22.61
35.28
12.23
39.58
10.82
42.19
15.04
Control
HDAC Inhibitor
Continuous
HDAC Inhibitor
IV
HDAC Inhibitor
Oral 2x
HDAC Inhibitor
Oral 3x

FIG. 3




PCI uM	Bendamustine uM	CI
0.05	25	0.463
0.05	50	0.579
0.05	100	0.481

PCI uM	Bendamustine uM	CI
0.1	25	0.673
0.1	50	0.240
0.1	100	0.324

PCI uM	Bendamustine uM	CI
0.2	25	0.282
0.2	50	0.172
0.2	100	0.216


PCI=HDAC inhibitor

FIG. 4




PCI= HDAC inhibitor

FIG. 5A




PCI= HDAC inhibitor

FIG. 5B



PCI= HDAC inhibitor

FIG. 6A



PCI= HDAC inhibitor

FIG. 6B




FIG. 6C




FIG. 7





H929 MM Xenograft Model
Vehicle
Bendamustine 5 mg/kg
HDAC Inhibitor 12mg/kg
HDAC Inhibitor + Bendamustine
Tumor Volume (mm3)
600
500
400
300
200
100
0
3
6
9
12
15
18
21
Study Day

FIG. 8




PCI= HDAC inhibitor

FIG. 9




PCI=HDAC inhibitor

FIG. 10



PCI-24781 = HDAC inhibitor

FIG. 11




PCI-24781 uM	Chloroquine uM	CI
0.1	25	1.264
0.1	50	1.093
0.1	100	0.92

PCI-24781 uM	Chloroquine uM	CI
0.2	25	0.977
0.2	50	0.895
0.2	100	0.457

PCI-24781 uM	Chloroquine uM	CI
0.4	25	1.070
0.4	50	0.572
0.4	100	0.379

PCI-24781 = HDAC inhibitor


FIG. 12



24781 uM	perifosine uM	CI
0.2	5	0.299
0.2	10	0.386
0.2	20	0.307

PCI-24781 = HDAC inhibitor

FIG. 13



PCI-24781 = HDAC inhibitor